Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial
Open Access
- 9 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 6 (1), 1-8
- https://doi.org/10.1038/s41392-021-00607-2
Abstract
We examined the safety and efficacy of human umbilical cord mesenchymal stem cell (hUC-MSC) infusion for immune non-responder (INR) patients with chronic HIV-1 infection, who represent an unmet medical need even in the era of efficient antiretroviral therapy (ART). Seventy-two INR patients with HIV were enrolled in this phase II randomized, double-blinded, multicenter, placebo-controlled, dose-determination trial (NCT01213186) from May 2013 to March 2016. They were assigned to receive high-dose (1.5 × 106/kg body weight) or low-dose (0.5 × 106/kg body weight) hUC-MSC, or placebo. Their clinical and immunological parameters were monitored during the 96-week follow-up study. We found that hUC-MSC treatment was safe and well-tolerated. Compared with baseline, there was a statistical increase in CD4+ T counts in the high-dose (P < 0.001) and low-dose (P < 0.001) groups after 48-week treatment, but no change was observed in the control group. Kaplan–Meier analysis revealed a higher cumulative probability of achieving an immunological response in the low-dose group compared with the control group (95.8% vs. 70.8%, P = 0.004). However, no significant changes in CD4/CD8+ T counts and CD4/CD8 ratios were observed among the three groups. In summary, hUC-MSC treatment is safe. However, the therapeutic efficacy of hUC-MSC treatment to improve the immune reconstitution in INR patients still needs to be further investigated in a large cohort study.Keywords
This publication has 26 references indexed in Scilit:
- Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trialStem Cells Translational Medicine, 2020
- Definition of Immunological Nonresponse to Antiretroviral Therapy: A Systematic ReviewJAIDS Journal of Acquired Immune Deficiency Syndromes, 2019
- [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)].2018
- Immunomodulatory placental‐expanded, mesenchymal stromal cells improve muscle function following hip arthroplastyJournal of Cachexia, Sarcopenia and Muscle, 2018
- Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNAAIDS, 2016
- CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort studyThe Lancet HIV, 2015
- Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patientsAIDS, 2013
- The Immunomodulatory Nutritional Intervention NR100157 Reduced CD4+ T-Cell Decline and Immune Activation: A 1-Year Multicenter Randomized Controlled Double-Blind Trial in HIV-Infected Persons Not Receiving Antiretroviral Therapy (The BITE Study)Clinical Infectious Diseases, 2013
- Incomplete Peripheral CD4+Cell Count Restoration in HIV‐Infected Patients Receiving Long‐Term Antiretroviral TreatmentClinical Infectious Diseases, 2009
- CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infectionAIDS, 2008